• Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive Phase 1/2 data for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, with all patients achieving hematologic responses.
• Patients with organ involvement also showed organ improvement, an outcome that is uncommon in amyloidosis trials.
• The registrational Phase 2 study of Lynozyfic in AL amyloidosis is ongoing, with detailed results expected to be presented at ASCO 2026.

For investors tracking Regeneron Pharmaceuticals, the Lynozyfic update comes at a time when the stock is trading at $638.88 and has been under pressure in the near term. The share price is down 8.5% over the past week and 14.4% over the past month, and is also down 17.7% year to date, while the 5-year return stands at 28.2%.

This new data point adds another late-stage asset to monitor in Regeneron’s pipeline, particularly outside of its more familiar oncology focus. Investors now have a clearer clinical marker to follow as the registrational Phase 2 progresses and the company moves toward the planned ASCO 2026 data presentation.

Stay updated on the most important news stories for Regeneron Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Regeneron Pharmaceuticals.

Quick Assessment

• ✅ Price vs Analyst Target: At US$638.88 versus a US$833.31 analyst target, the stock trades about 23% below consensus.
• ✅ Simply Wall St Valuation: Shares are flagged as trading about 70.2% below an internal fair value estimate.
• ❌ Recent Momentum: The stock has fallen 14.4% over the past 30 days.

To assess whether it could be the right time to buy, sell or hold Regeneron Pharmaceuticals, you can review Simply Wall St's company report for the latest analysis of Regeneron Pharmaceuticals's Fair Value.

Key Considerations

• 📊 Positive Lynozyfic data in AL amyloidosis adds a fresh late stage asset that sits alongside existing revenue drivers.
• 📊 Watch progress of the registrational Phase 2 study, future safety updates and any commentary on potential market size for this indication.
• ⚠️ Even with encouraging early data, binary clinical risk remains until larger, controlled trials in AL amyloidosis read out.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Regeneron Pharmaceuticals analysis. Alternatively, you can check out the community page for Regeneron Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.